Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Compare

1,733 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JAZZ Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Jazz

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$179.45

▲(58.99%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $179.45 with a high forecast of $230.00 and a low forecast of $147.00. The average price target represents a 58.99% change from the last price of $112.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","168":"$168","231":"$231","136.5":"$136.5","199.5":"$199.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$230.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$179.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$147.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,136.5,168,199.5,231],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.44,118.71384615384615,127.9876923076923,137.26153846153846,146.5353846153846,155.80923076923077,165.08307692307693,174.35692307692307,183.63076923076923,192.9046153846154,202.17846153846153,211.4523076923077,220.72615384615386,{"y":230,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.44,114.8253846153846,120.21076923076923,125.59615384615384,130.98153846153846,136.36692307692306,141.75230769230768,147.1376923076923,152.52307692307693,157.90846153846152,163.29384615384615,168.67923076923074,174.06461538461537,{"y":179.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,109.44,112.32923076923076,115.21846153846154,118.1076923076923,120.99692307692308,123.88615384615385,126.77538461538461,129.6646153846154,132.55384615384617,135.44307692307692,138.3323076923077,141.22153846153844,144.11076923076922,{"y":147,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.47,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$230.00

Average Price Target$179.45

Lowest Price Target$147.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$127

Buy

12.52%

Upside

Reiterated

07/11/25

Jazz Pharmaceuticals exhibits a strong financial profile and strategic growth initiatives. Robust cash flow and neuroscience performance are key strengths, while moderate leverage and oncology challenges are risks.

Mohit BansalWells Fargo

Wells Fargo

$170

Buy

50.62%

Upside

Reiterated

07/18/25

Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)

David HoangDeutsche Bank

Deutsche Bank

$152

Buy

34.67%

Upside

Initiated

07/15/25

Jazz Pharmaceuticals initiated with a Buy at Deutsche BankJazz Pharmaceuticals initiated with a Buy at Deutsche Bank

Leonid TimashevRBC Capital

RBC Capital

$172→$167

Buy

47.96%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/11/25

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial

Ami FadiaNeedham

Needham

$202

Buy

78.97%

Upside

Assigned

06/11/25

Jazz Pharmaceuticals: Strategic Expansion of Zepzelca Drives Buy Rating Amid Growth Potential

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/11/25

Jazz Pharmaceuticals: Promising Developments in ES-SCLC and Anticipated Stock Growth

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$230

Buy

103.77%

Upside

Reiterated

06/11/25

Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Joseph ThomeTD Cowen

TD Cowen

$205

Buy

81.62%

Upside

Reiterated

06/11/25

TD Cowen Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Gary NachmanRaymond James

Raymond James

―

Hold

―

Reiterated

06/11/25

Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

Sean LaamanMorgan Stanley

Morgan Stanley

$166

Buy

47.07%

Upside

Reiterated

06/10/25

Buy Rating for Jazz Pharmaceuticals: Promising Clinical Trial Results and Market Potential of Zepzelca

David AmsellemPiper Sandler

Piper Sandler

$147

Buy

30.24%

Upside

Reiterated

06/03/25

Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Ashwani VermaUBS

UBS

$166→$164

Buy

45.30%

Upside

Reiterated

06/03/25

UBS Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Jason GerberryBank of America Securities

Bank of America Securities

$216

Buy

91.37%

Upside

Reiterated

06/02/25

Bank of America Securities Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Joel BeattyRobert W. Baird

Robert W. Baird

$167→$155

Buy

37.33%

Upside

Reiterated

05/07/25

Jazz Pharmaceuticals price target lowered to $155 from $167 at BairdJazz Pharmaceuticals price target lowered to $155 from $167 at Baird

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$127

Buy

12.52%

Upside

Reiterated

07/11/25

Mohit BansalWells Fargo

Wells Fargo

$170

Buy

50.62%

Upside

Reiterated

07/18/25

Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)

David HoangDeutsche Bank

Deutsche Bank

$152

Buy

34.67%

Upside

Initiated

07/15/25

Jazz Pharmaceuticals initiated with a Buy at Deutsche BankJazz Pharmaceuticals initiated with a Buy at Deutsche Bank

Leonid TimashevRBC Capital

RBC Capital

$172→$167

Buy

47.96%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/11/25

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial

Ami FadiaNeedham

Needham

$202

Buy

78.97%

Upside

Assigned

06/11/25

Jazz Pharmaceuticals: Strategic Expansion of Zepzelca Drives Buy Rating Amid Growth Potential

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/11/25

Jazz Pharmaceuticals: Promising Developments in ES-SCLC and Anticipated Stock Growth

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$230

Buy

103.77%

Upside

Reiterated

06/11/25

Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Joseph ThomeTD Cowen

TD Cowen

$205

Buy

81.62%

Upside

Reiterated

06/11/25

TD Cowen Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Gary NachmanRaymond James

Raymond James

―

Hold

―

Reiterated

06/11/25

Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

Sean LaamanMorgan Stanley

Morgan Stanley

$166

Buy

47.07%

Upside

Reiterated

06/10/25

Buy Rating for Jazz Pharmaceuticals: Promising Clinical Trial Results and Market Potential of Zepzelca

David AmsellemPiper Sandler

Piper Sandler

$147

Buy

30.24%

Upside

Reiterated

06/03/25

Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Ashwani VermaUBS

UBS

$166→$164

Buy

45.30%

Upside

Reiterated

06/03/25

UBS Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Jason GerberryBank of America Securities

Bank of America Securities

$216

Buy

91.37%

Upside

Reiterated

06/02/25

Bank of America Securities Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Joel BeattyRobert W. Baird

Robert W. Baird

$167→$155

Buy

37.33%

Upside

Reiterated

05/07/25

Jazz Pharmaceuticals price target lowered to $155 from $167 at BairdJazz Pharmaceuticals price target lowered to $155 from $167 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

1 Month

xxx

Success Rate

25/41 ratings generated profit

Average Return

+0.29%

assigned a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.98% of your transactions generating a profit, with an average return of +0.29% per trade.

3 Months

xxx

Success Rate

25/41 ratings generated profit

Average Return

+1.56%

assigned a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.98% of your transactions generating a profit, with an average return of +1.56% per trade.

1 Year

Annabel SamimyStifel Nicolaus

Success Rate

17/29 ratings generated profit

Average Return

+3.14%

reiterated a buy rating last month

Copying Annabel Samimy's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +3.14% per trade.

2 Years

xxx

Success Rate

21/40 ratings generated profit

Average Return

+2.42%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.50% of your transactions generating a profit, with an average return of +2.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JAZZ has received 34 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 179.45.

Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is -$7.62 with a range of -$9.37 to -$4.38. The previous quarter’s EPS was $1.68. JAZZ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.04B with a range of $988.65M to $1.08B. The previous quarter’s sales results were $897.84M. JAZZ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 179.45.

What is JAZZ’s upside potential, based on the analysts’ average price target?

Jazz Pharmaceuticals has 58.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JAZZ a Buy, Sell or Hold?

Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Jazz Pharmaceuticals’s price target?

The average price target for Jazz Pharmaceuticals is 179.45. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $230.00 ,the lowest forecast is $147.00. The average price target represents 58.99% Increase from the current price of $112.87.

What do analysts say about Jazz Pharmaceuticals?

Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of JAZZ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

JAZZ Analyst Ratings

JAZZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jazz Pharmaceuticals

JAZZ Analyst Recommendation Trends

JAZZ Financial Forecast

JAZZ Earnings Forecast

JAZZ Sales Forecast

JAZZ Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts